Two molecules help ß-lactams kill drug resistant bacteria

Bacteria developing resistance to antibiotics has been well publicised, one such type in particular, Staphylococcus aureus, (MRSA) has become particularly troublesome—it is one of the more common bacteria types that cause staph infections, and has become immune to attack by ß-lactams, which include penicillin.

Research has shown that one of the ways that MRSA became able to ward off attacks by ß-lactams was by fortifying its cell walls using building blocks known as teichoic acid. Prior research has also led to the discovery of molecules that are able to disrupt the building of such walls in their latter stages, but thus far have not proven to be effective in helping reduce resistance in MRSA.

In this new effort, the researchers conducted an exhaustive search of molecules capable of interfering with the early stages of wall development, by building each molecule from scratch and testing it with another chemical that was known to inhibit later stage growth.

The team reports that two molecules they created, tarocin A and B, were able to interrupt wall building at an early stage, which then allowed a dose of ß-lactams to move in for the kill.

Once the molecules were identified, the team set about bolstering their abilities and then conducted multiple tests of the abilities of both to help treat bacterial infections. They report that the combination proved successful in 82% of lab samples tested against MRSA and 72 percent effective against another common resistant bacteria known as MRSE.

They also tested the combinations in mice infected with MRSA—those that got the double dose treatment showed signs of reduced infection, while those given just one of the drugs did not improve at all. Furthermore, the researchers also report that initial testing indicates that neither new molecule appears to cause any harm to human cells.